Evidence map›Paper›PMID 37471577›Full record

ArticleJournal of the American Chemical Society2023

μMap Photoproximity Labeling Enables Small Molecule Binding Site Mapping.

Sean W Huth, James V Oakley, Ciaran P Seath, Jacob B Geri, Aaron D Trowbridge, Dann L Parker, Frances P Rodriguez-Rivera, Adam G Schwaid, Carlo Ramil, Keun Ah Ryu and 4 more

Abstract read
In one paragraph

Article in Journal of the American Chemical Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. 2-Alkyl Furans Undergo Radiolytic Oxidative Protein Cross-Linking.Journal of the American Chemical Society · 2026
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sean W HuthMerck Center for Catalysis at Princeton University, Princeton, New Jersey 08544, United States.
James V OakleyMerck Center for Catalysis at Princeton University, Princeton, New Jersey 08544, United States.
Ciaran P SeathMerck Center for Catalysis at Princeton University, Princeton, New Jersey 08544, United States.
Jacob B GeriMerck Center for Catalysis at Princeton University, Princeton, New Jersey 08544, United States.ORCID 0000-0002-9215-5610
Aaron D TrowbridgeMerck Center for Catalysis at Princeton University, Princeton, New Jersey 08544, United States.
Dann L ParkerDiscovery Chemistry, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States.
Frances P Rodriguez-RiveraDiscovery Chemistry, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States.ORCID 0000-0003-0651-8639
Adam G SchwaidDiscovery Chemistry, Merck & Co., Inc., Cambridge, Massachusetts 02141, United States.ORCID 0000-0003-2434-6148
Carlo RamilDiscovery Chemistry, Merck & Co., Inc., Cambridge, Massachusetts 02141, United States.ORCID 0000-0002-1036-855X
Keun Ah RyuMerck Exploratory Science Center, Merck & Co., Inc., Cambridge, Massachusetts 02141, United States.
Cory H WhiteMerck Exploratory Science Center, Merck & Co., Inc., Cambridge, Massachusetts 02141, United States.
Olugbeminiyi O FadeyiMerck Exploratory Science Center, Merck & Co., Inc., Cambridge, Massachusetts 02141, United States.ORCID 0000-0002-5525-1304
Rob C OslundMerck Exploratory Science Center, Merck & Co., Inc., Cambridge, Massachusetts 02141, United States.
David W C MacMillanMerck Center for Catalysis at Princeton University, Princeton, New Jersey 08544, United States.ORCID 0000-0001-6447-0587

Funding

Resource for Biocomputing Visualization and InformaticsP41GM103311 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2012 to 2017
$8.2M
Photoredox Catalysis Applications in Organometallics and Chemical BiologyR35GM134897 · NIGMS · PRINCETON UNIVERSITY · PI David W MacMillan · 2020 to 2026
$6.3M
NIGMS NIH HHS P41 GM103311NIGMS NIH HHS R35 GM134897
6 · The paper itself

Abstract

The characterization of ligand binding modes is a crucial step in the drug discovery process and is especially important in campaigns arising from phenotypic screening, where the protein target and binding mode are unknown at the outset. Elucidation of target binding regions is typically achieved by X-ray crystallography or photoaffinity labeling (PAL) approaches; yet, these methods present significant challenges. X-ray crystallography is a mainstay technique that has revolutionized drug discovery, but in many cases structural characterization is challenging or impossible. PAL has also enabled binding site mapping with peptide- and amino-acid-level resolution; however, the stoichiometric activation mode can lead to poor signal and coverage of the resident binding pocket. Additionally, each PAL probe can have its own fragmentation pattern, complicating the analysis by mass spectrometry. Here, we establish a robust and general photocatalytic approach toward the mapping of protein binding sites, which we define as identification of residues proximal to the ligand binding pocket. By utilizing a catalytic mode of activation, we obtain sets of labeled amino acids in the proximity of the target protein binding site. We use this methodology to map, in vitro, the binding sites of six protein targets, including several kinases and molecular glue targets, and furthermore to investigate the binding site of the STAT3 inhibitor MM-206, a ligand with no known crystal structure. Finally, we demonstrate the successful mapping of drug binding sites in live cells. These results establish μMap as a powerful method for the generation of amino-acid- and peptide-level target engagement data.

Indexed as

PeptidesProteinsBinding SitesLigandsProtein BindingLigandsPeptidesProteins

Identifiers

PMID37471577
PMCPMC10809032

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.